Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

Murat Özbalak Metban Güzel Mastanzade Özden Özlük Tarık Onur Tiryaki Sevgi Kalayoğlu-Beşışık Ezgi Pınar Özbalak Tuğrul Elverdi Ipek Yonal Hindilerden Ali Yılmaz Altay Gulcin Yegen Ahmet Emre Eskazan Muhlis Cem Ar Mustafa Nuri Yenerel Teoman Soysal Meliha Nalçacı Burhan Ferhanoğlu Sevgi Kalayoglu Besisik

Published in: Turkish journal of haematology : official journal of Turkish Society of Haematology (2022)

RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
monoclonal antibody
squamous cell carcinoma
blood brain barrier
deep learning
free survival
locally advanced
artificial intelligence
hodgkin lymphoma